Diabetic peripheral neuropathy: Resource utilization and burden of illness

Journal of Medical Economics

Volumn 17, Issue 9, 2014, Pages 637-645

  Mehra, Maneesha ^a   Merchant, Sanjay ^a   Gupta, Shikha ^b   Potluri, Ravi C ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b SmartAnalyst India Pvt Ltd ^*  (India)

^c SmartAnalyst   (United States)

Author keywords

Claims database; Diabetic peripheral neuropathy; DPN; Economic burden; Medical resource utilization

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREGABALIN;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BACKACHE; COST OF ILLNESS; DEPRESSION; DIABETIC NEUROPATHY; DIABETIC PERIPHERAL NEUROPATHY; DRUG USE; ECONOMIC EVALUATION; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NECK PAIN; OSTEOARTHRITIS; PERIPHERAL NEUROPATHY; PHARMACEUTICAL CARE; PHARMACY; POSTHERPETIC NEURALGIA; RETROSPECTIVE STUDY; SLEEP DISORDER; VERY ELDERLY; ADOLESCENT; AGE; COMORBIDITY; DIABETIC NEUROPATHIES; ECONOMICS; HEALTH CARE COST; HEALTH SERVICE; INSURANCE; MIDDLE AGED; PAIN; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COMORBIDITY; DIABETIC NEUROPATHIES; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PAIN; SEX FACTORS; YOUNG ADULT;

EID: 84906538642     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.928639     Document Type: Article

References (37)

1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5
2. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: Update on Definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285-93
3. Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2000;43:957-73
4. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003;26:1790-5
5. Rathur HM, Boulton AJ. Recent advances in the diagnosis and management of diabetic neuropathy. J Bone Joint Surg Br 2005;87:1605-10
6. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43:817-24
7. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377-84
8. Gore M, Brandenburg NA, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: The patients perspectives. J Pain 2006;7:892-900
9. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012;28(1 Suppl):8-14
10. Le TK, Able SL, Lage MJ. Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression. Cost Eff Resour Alloc 2006;4:18
11. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005;28:956-62
12. Boyko EJ, Ahroni JH, Smith DG, et al. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996;13:967-72
13. Ding J, Cheung CY, Ikram MK, et al. Early retinal arteriolar changes and peripheral neuropathy in Diabetes. Diabetes Care 2012;35:1098-104
14. Davies M, Brophy S, Williams R, et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-22
15. Melton III LJ, Dyck PJ. Diabetic polyneuropathy. In: Dyck PJ, Thomas PK, eds. Diabetic neuropathy. 2nd edn. Philadelphia, PA: W.B. Saunders, 1999. pp. 255-78
16. Lindsay TJ, Rodgers BC, Savath V, Hettinger K. Treating diabetic peripheral neuropathic pain. Am Fam physician 2010;82:151-8
17. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: Consensus recommendations on Diagnosis, assessment and management. Diabetes Metab Res Rev 2011;27:629-38
18. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81
19. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: Epidemiology, pain Description, and quality of life. Diabetes Res Clin Pract 2000;47:123-8
20. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Qjm 1998;91:733-7
21. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280:1831-6
22. Dworkin RH. An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002;18:343-9
23. Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain 2000;16(2 Suppl):S101-5
24. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998;280:1837-42
25. Hiatt WR, Hoag S, Hamman RF. Effect of Diagnostic Criteria on the Prevalence of Peripheral Arterial Disease. Circulation 1995;91:1472-9
26. IMS LifeLink. LifeLink Health Plan Claims Database. Overview and Study Design Issues. 2010. American Medical Association, http:// www.uams.edu/TRI/ hsrcore/Lifelink-Health-Plan-Claims-Data- DesignIssues-wcost-April2010[1].pdf. Accessed February 7, 2014
27. Vileikyte L, Peyrot M, Gonzalez JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: A longitudinal study. Diabetologia 2009;52:1265-73
28. Sandercock D, Cramer M, Wu J, et al. Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: Efficacy and tolerability in a double-blind, randomized, controlled clinical trial. Diabetes Care 2009;32:e20
29. Younger DS. Diabetic neuropathy: A clinical and neuropathological study of 107 patients. Neurol Res Int 2010;2010:140379
30. Viala-Danten M, Martin S, Guillemin I, et al. Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial. Health Qual Life Outcomes 2008;6:113
31. Wade RL, Cai Q. Impact of L-Methylfolate combination therapy among diabetic peripheral neuropathy patients. American Journal of Pharmacy benefits updated 17 Oct 2012. http://www.ajmc.com/publications/ajpb/2012/ AJPB-SepOct2012/Impact-of-L-Methylfolate-Combination-Therapy-Among-Diabetic- Peripheral-Neuropathy-Patients. Accessed February 7, 2014
32. News from the Arthritis Foundation. 2008. Arthritis Foundation, Atlanta, GA, http://www.arthritis.org/files/images/newsroom/media-kits/ Osteoarthritis-fact-sheet.pdf. Accessed February 7, 2014
33. Osteoarthritis Costs U.S. Over $185 Billion a Year. 2009. Health Day, http:// health.usnews.com/health-news/family-health/pain/articles/2009/11/ 30/ osteoarthritis-costs-us-over-185-billion-A-year. Accessed February 7, 2014
34. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-14
35. Dworkin RH, O"Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51
36. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005;118:289-305
37. Wu CL, Agarwal S, Tella PK, et al. Morphine versus mexiletine for treatment of postamputation pain: A randomized, placebo-controlled, crossover trial. Anesthesiology 2008;109:289-96